title: Gynecomastia in a male after dasatinib treatment for chronic myeloid leukemia.
authors.forename: G
authors.initials: G
authors.lastname: Caocci
authors.forename: S
authors.initials: S
authors.lastname: Atzeni
authors.forename: N
authors.initials: N
authors.lastname: Orrù
authors.forename: L
authors.initials: L
authors.lastname: Azzena
authors.forename: L
authors.initials: L
authors.lastname: Martorana
authors.forename: R
authors.initials: R
authors.lastname: Littera
authors.forename: A
authors.initials: A
authors.lastname: Ledda
authors.forename: G
authors.initials: G
authors.lastname: La Nasa
mesh_terms: D000368:Aged; D000069439:Dasatinib; D006177:Gynecomastia / Q000139:chemically induced* / Q000188:drug therapy; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy*; D008297:Male; D047428:Protein Kinase Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D011743:Pyrimidines / Q000009:adverse effects* / Q000627:therapeutic use; D020845:Selective Estrogen Receptor Modulators / Q000627:therapeutic use; D013629:Tamoxifen / Q000627:therapeutic use; D013844:Thiazoles / Q000009:adverse effects* / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D020845:Selective Estrogen Receptor Modulators; D013844:Thiazoles; D013629:Tamoxifen; D000069439:Dasatinib